27 related articles for article (PubMed ID: 7808038)
1. An anticonvulsive drug, valproic acid (valproate), has effects on the biosynthesis of fatty acids and polyketides in microorganisms.
Poolchanuan P; Unagul P; Thongnest S; Wiyakrutta S; Ngamrojanavanich N; Mahidol C; Ruchirawat S; Kittakoop P
Sci Rep; 2020 Jun; 10(1):9300. PubMed ID: 32518288
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid and bladder healing: an experimental study in rats.
Biondo-Simões MLP; Dall'antonia MO; Goehr MP; Biondo-Simões R; Ioshii SO; Robes RR
Rev Col Bras Cir; 2022; 49():e20223399. PubMed ID: 36449944
[TBL] [Abstract][Full Text] [Related]
3. 1-Methyl-1,2,3,4-tetrahydroisoquinoline enhances the anticonvulsant action of carbamazepine and valproate in the mouse maximal electroshock seizure model.
Luszczki JJ; Antkiewicz-Michaluk L; Czuczwar SJ
Neuropharmacology; 2006 Feb; 50(2):133-42. PubMed ID: 16153667
[TBL] [Abstract][Full Text] [Related]
4. Preliminary evaluation of the anticonvulsant activity of a valproic acid analog: N-(2-propylpentanoyl) urea.
Tantisira B; Tantisira MH; Patarapanich C; Sooksawate T; Chunngam T
Res Commun Mol Pathol Pharmacol; 1997 Aug; 97(2):151-64. PubMed ID: 9344228
[TBL] [Abstract][Full Text] [Related]
5. 2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice.
Luszczki JJ; Mohamed M; Czuczwar SJ
Eur J Pharmacol; 2006 Feb; 531(1-3):66-73. PubMed ID: 16403497
[TBL] [Abstract][Full Text] [Related]
6. Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model.
Luszczki JJ; Czuczwar P; Cioczek-Czuczwar A; Czuczwar SJ
Eur J Pharmacol; 2006 Oct; 547(1-3):65-74. PubMed ID: 16930590
[TBL] [Abstract][Full Text] [Related]
7. Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate.
Della Paschoa OE; Voskuyl RA; Danhof M
Br J Pharmacol; 1998 Dec; 125(7):1610-6. PubMed ID: 9884091
[TBL] [Abstract][Full Text] [Related]
8. The effects of sodium valproate and its metabolites (5-OH-VPA and 4-OH-VPA) on electroconvulsions in rats.
Sobaniec W; Sobaniec-Lotowska M
Mater Med Pol; 1994; 26(1):29-32. PubMed ID: 7808038
[TBL] [Abstract][Full Text] [Related]
9. Valproate and valproate-analogues: potent tools to fight against cancer.
Blaheta RA; Nau H; Michaelis M; Cinatl J
Curr Med Chem; 2002 Aug; 9(15):1417-33. PubMed ID: 12173980
[TBL] [Abstract][Full Text] [Related]
10. Valproate: past, present, and future.
Johannessen CU; Johannessen SI
CNS Drug Rev; 2003; 9(2):199-216. PubMed ID: 12847559
[TBL] [Abstract][Full Text] [Related]
11. Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile.
Mishra MK; Kukal S; Paul PR; Bora S; Singh A; Kukreti S; Saso L; Muthusamy K; Hasija Y; Kukreti R
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011339
[TBL] [Abstract][Full Text] [Related]
12. Sodium valproate.
Kupferberg HJ
Adv Neurol; 1980; 27():643-54. PubMed ID: 6769305
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
